British HIV association and children's HIV association guidelines for the management of HIV infection in pregnant women 2008

HIV Medicine

Volumn 9, Issue 7, 2008, Pages 452-502

  de Ruiter, Annemiek ^a,m   Mercey, D ^b   Anderson, J ^c   Chakraborty, R ^d   Clayden, P ^e   Foster, G ^f   Gilling Smith, C ^g   Hawkins, D ^g   Low beer, N ^h   Lyall, H ⁱ   O'shea, S ^a   Penn, Z ^g   Short, J ^j   Smith, R ^g   Sonecha, S ^k   Tookey, P ^l   Wood, C ^k   Taylor, G ^h  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e c o HIV i Base   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^j UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^k NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m ST THOMAS HOSPITAL   (United Kingdom)

more..

Author keywords

Antiretrovirals; Caesarean section; HIV; Pregnancy; Prematurity; Transmission

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CORTICOSTEROID; COTRIMOXAZOLE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTEPARTUM HEMORRHAGE; ANTIVIRAL RESISTANCE; CHILD HEALTH CARE; CLINICAL TRIAL; DELIVERY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG WITHDRAWAL; EMBRYOTOXICITY; EVIDENCE BASED MEDICINE; FETOTOXICITY; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFANT DISEASE; INFANT FEEDING; LABORATORY TEST; LACTATION INHIBITION; LACTIC ACIDOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OBSTETRIC CARE; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PEER GROUP; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROLONGED PREGNANCY; PUERPERIUM; REVIEW; SEROCONVERSION; SEXUAL HEALTH; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SUPERINFECTION; TOXIC HEPATITIS; UNITED KINGDOM; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DELIVERY, OBSTETRIC; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL HEALTH SERVICES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 50149116804     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00619.x     Document Type: Review

References (315)

1. The Health Protection Agency. A Complex Picture. HIV and other Sexually Transmitted Infections in the United Kingdom: 2006. http://www.hpa.org.uk/publications/ PublicationDisplay.asp?PublicationID=55 2006 [accessed 5 August 2007].
2. Tookey P. National Study of HIV in Pregnancy and Childhood. http://www.nshpc.ucl.ac.uk 2008.
3. Townsend C, Cortina-Borja M, Peckham C, Tookey P. MTCT of HIV in the United Kingdom and Ireland, 1990-2004. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 761].
4. Townsend C, Cortina-Borja M, Peckham C, Lyall H, de Ruiter A, Tookey P. Very low risk of mother-to-child transmission of HIV in women on HAART achieving viral suppression in the UK and Ireland. AIDS 2008; 22: 973-981.
5. Cooper ER, Charurat M, Mofenson LM et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Sydnr 2002; 29: 484-494.
6. Intercollegiate Working Party. Reducing Mother -to- Child Transmission of HIV Infection in the United Kingdom. http://www.rcpch.ac.uk/ publications/recent_publications/HIVreport.pdf 2006 [accessed 23 February 2007].
7. NHS Executive. Reducing mother-to-baby transmission of HIV. HSC 1999/ 183. London, Department of Health. Health Services Circular 1999. http://www.dh.gov.uk/assetRoot/04/01/21/28/04012128.pdf 1999 [accessed 23 February 2007].
8. Townsend CL, Cliffe S, Tookey PA. Uptake of antenatal HIV testing in the United Kingdom: 2000-2003. J Public Health 2006; 28: 248-252.
9. Department of Health. Standards to Support the UK Antenatal Screening Programme. August 2003. http://www.dh.gov.uk/ 2003 [accessed 23 February 2003].
10. De Vincenzi I. The European Study Group on Heterosexual Transmission of HIV. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 1994; 331: 341-346.
11. Castilla J, del Romero J, Hernando V, Marincovich M, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Sydnr 2005; 40: 96-101.
12. Zhang H, Dornadula G, Beumont M et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339: 1803-1809.
13. Coombs R, Speck CE, Hughes JP et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998; 177: 320-330.
14. Mandelbrot L, Heard I, Henrion-Geant E, Henrion R. Natural conception in HIV-negative women with HIV-infected partners. Lancet 1997; 349: 850-851.
15. Barreiro P, del Romero J, Leal M et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Sydnr 2006; 43: 324-326.
16. Semprini AE, Levi-Setti P, Bozzo M et al. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 1992; 340: 1317-1319.
17. Gilling-Smith C. HIV prevention. Assisted reproduction in HIV-discordant couples. AIDS Reader 2000; 10: 581-587.
18. Gilling-Smith C, Nicopoullos JDM, Semprini AE, Frodsham LCG. HIV and reproductive care -a review of current practice. Br J Obstet Gynaecol 2006; 113: 869-878.
19. Bujan L, Hollander L, Couvert M et al. Safety and efficacy of sperm washing in HIV-1 serodiscordant couples where the male is infected: results from the European CREAThE network. AIDS 2007; 21: 1909-1914.
20. National Institute for Health and Clinical Excellence. NICE Guidelines. Management of couples with viral infections. Fertility assessment and treatment for people with fertility problems. Available online: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=10936 2004.
21. Gilling-Smith C, Almeida P. Practice Policy Committee of the British Fertility Society. HIV, hepatitis B and hepatitis C and infertility: reducing risk. Hum Fertil (Cambridge) 2003; 6: 106-112.
22. Smith DM, Wong JK, Hightower GK et al. HIV drug resistance acquired through superinfection. AIDS 2005; 19: 1251-1256.
23. Gonzales MJ, Delwart E, Rhee SY et al. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis 2003; 188: 397-405.
24. Sauer MV. Providing fertility care to those with HIV: Time to re-examine healthcare policy. Am J Bioeth 2003; 3: 33-40.
25. Frodsham LC, Smith JR, Gilling-Smith C. Assessment of welfare of the child in HIV-positive couples. Hum Reprod 2004; 19: 2420-2423.
26. Gilling-Smith C. Risking parenthood? Serious viral illness, parenting and welfare of the child. In: Shenfield F, Sureau C, eds. Contemporary Ethical Dilemmas in Assisted Reproduction. London, CRC Press, 2006: 57-69.
27. The Practice Committee of the American Society for Reproductive Medicine. Hepatitis and reproduction. Fertility and Sterility 2004; 82: 1754-1764.
28. Madge S, Phillips AN, Griffioen A, Olaitan A, Johnson MA. Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of Women with HIV. Int J Epidemiol 1998; 27: 1068-1071.
29. Leroy V, De Clerq A, Ladner J, Bogaerts J, Van der Perre P, Dabis F. Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? A prospective cohort study from Kigali, Rwanda, 1992-1993. The Pregnancy and HIV (EGE) Group. Genitourin Med 1995; 71: 207-211.
30. Low N, Sterne JAC, Barlow D. Inequalities in rates of gonorrhoea and chlamydia between black ethnic groups in south east London: Cross sectional study. Sex Transm Infect 2001; 77: 15-20.
31. Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. New Engl J Med 1988; 319: 972-978.
32. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. New Engl J Med 2000; 342: 1500-1507.
33. Landesman SH, Kalish LA, Burns DN et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. New Engl J Med 1996; 334: 1617-1623.
34. The European Collaborative Study. Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10: 1675-1681.
35. Van Dyke RB, Korber BT, Popek E et al. The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999; 179: 319-328.
36. Hillier SL, Nugent RP, Eschenbach DA et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. New Engl J Med 1995; 333: 1737-1742.
37. Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann NY Acad Sci 2000; 918: 84-98.
38. McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2003, (CD000262).
39. Varma R, Gupta JK, James DK, Kilby MD. Do screening-preventative interventions in asymptomatic pregnancies reduce the risk of preterm delivery -a critical appraisal of the literature. Eur J Obstetr Gynecol Reproduct Biol 2006; 127: 145-159.
40. Cameron DW, Simonsen JN, D'Costa LJ et al. Female-to-male transmission of human immunodeficiency virus type 1: Risk factors for seroconversion in men. Lancet 1989; 2: 403-407.
41. Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex Transm Dis 1996; 23: 429-440.
42. Ghys PD, Fransen K, Diallo MO et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997; 11: F85-F93.
43. Lawn SD, Subbarao S, Wright JTC et al. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis 2000; 181: 1950-1956.
44. Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: Results of a case control study. AIDS 2008; 22: 193-201.
45. Whitehead S, Bollen L, Leelawiwat W et al. Maternal HSV2 cervicovaginal shedding increases the risk of intrapartum HIV-1 transmission. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 25-28 February 2007 [Abstract 75].
46. Ouedraogo A, Nagot N, Vergne L et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20: 2305-2313.
47. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Aciclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: A systematic review. Obstet Gynecol 2003; 102: 1396-1403.
48. Hashemi FB, Ghassemi M, Roebuck KA, Spear GT. Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. J Infect Dis 1999; 179: 924-930.
49. Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT. Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis. J Infect Dis 2000; 181: 1574-1580.
50. McClelland RS, Wang CC, Mandaliya K et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15: 105-110.
51. Chuachoowong R, Shaffer N, Siriwasin W et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 2000; 181: 99-106.
52. Hart CE, Lennox JL, Pratt-Palmore M et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and female genital tract. J Infect Dis 2000; 179: 871-882.
53. Fiore JR, Suligoi B, Saracino A et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17: 169-176.
54. Kovacs A, Wasserman SS, Burns D et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358: 1593-1601.
55. de Pasquale MP, Leigh-Brown AJ, Cu-Uvin S et al. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Sydnr 2003; 34: 37-44.
56. Wood C, Kumalo P, Ainsworth J, Govind A, Meates M. Disclosure, discordance and decisions -the psychosocial impact of antenatal HIV testing. 6th International Congress On Drug Therapy in HIV Infection. Glasgow, UK, November 2002. [Abstract P319].
57. Wood C, Ellison G. What have clinicians learnt from working with HIV/ AIDS? A medical perspective from London, In: Ellison G, Parker M, Campbell C. eds. Learning from HIV/AIDS. Cambridge, Cambridge University Press, 2003: 105-137.
58. Siriwasin, Wimol MD et al. HIV prevalence, risk, and partner discordance among pregnant women in Bangkok. JAMA 1998; 280: 49-54.
59. Lurie M, Williams B, Zuma K et al. Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS 2003; 17: 2245-2252.
60. Guilen AC, Fogarty L, O'Campo P, Anderson J, Keller J, Faden R. Women living with HIV: Disclosure, violence, and social support. J Urban Health 2000; 77: 480-491.
61. Stein MD, Freedberg KA, Sullivan LM et al. Sexual ethics. Disclosure of HIV positive status to partners. Arch Intern Med 1998; 158: 253-257.
62. Potterat JJ. Partner notification for HIV: Running out of excuses. Sexually Transmitted Diseases 2003; 30: 89-90.
63. World Health Organization. Opening up the HIV epidemic: Guidance on encouraging beneficial disclosure. http://www.who.int/entity/hiv/pub/vct/ en/Opening-E%5B1%5D.pdf 2005.
64. General Medical Council. Serious Communicable Diseases. London, General Medical Council, 1997.
65. Serovich J. Helping HIV-positive persons to negotiate the disclosure process to partners, family members, and friends. J Marital Fam Ther 2000; 26: 365-372.
66. Freeman E, Glynn J, for the Study Group on Heterogeneity of HIV epidemics in African cities. Factors affecting HIV concordancy in married couples in four African cities. AIDS 2004; 18: 1715-1720.
67. Creighton S, Sethi G, Edwards SG, Miller R. Dispersal of HIV-positive asylum seekers: National survey of UK healthcare providers. BMJ 2004; 329: 322-323.
68. National AIDS Trust and British HIV Association. The Dispersal Process for Asylum Seekers living with HIV; Advice for health care and voluntary sector professionals. London, National AIDS Trust, 2006.
69. The UK Chief Medical Officers' Expert Advisory Group on AIDS, Department of Health. HIV and Infant Feeding. Available from: http://www.dh.gov.uk/ en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_4089892
70. Garcia PM, Kalish LA, Pitt J et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. New Engl J Med 1999; 341: 394-402.
71. Shaffer N, Chuachoowong R, Mock PA et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 1999; 353: 773-780.
72. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one. AIDS 1999; 13: 1377-1385.
73. Coll O, Hernandez M, Boucher C et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 26-30.
74. Ioannidis JP, Abrams EJ, Ammann AJ et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000copies/mL. J Infect Dis 2001; 183: 539-545.
75. Sperling RS, Shapiro DE, Coombs RW et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. New Engl J Med 1996; 335: 1621-1629.
76. Goulston C, McFarland W, Katzenstein D. Human immunodeficiency virus type 1 RNA shedding in the female genital tract. J Inf Dis 1998; 177: 1100-1103.
77. Si-Mohamed A, Kazatchkine MD, Heard I et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Inf Dis 2000; 182: 112-122.
78. Shaheen F, Sison A, McIntosh L, Mukhtar M, Pomerantz RJ. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 1999; 2: 156-166.
79. Mullen J, O'Shea S, Cormack I, Mears A, Magaya V, de Ruiter A. Antiretroviral drug resistance and genetic diversity of HIV-1 in the blood and female genital tract. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 956].
80. Kemal KS, Burger H, Mayers D et al. HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007; 195: 535-545.
81. Highbarger H, Alvord W, Jiang M et al. Comparison of the Quantiplex version 3.0 assay and a sensitised Amplicor Monitor assay for measurement of human immunodeficiency virus type I RNA levels in plasma samples. J Clin Microbiol 1999; 37: 3612-3614.
82. Braun P, Ehret R, Wiesmann F et al. Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin Chem Lab Med 2007; 45: 93-99.
83. Parry J, Murphy G, Barlow K et al. National surveillance of HIV-1 subtypes for England and Wales: Design, methods and initial findings. J Acquir Immune Defic Sydnr 2001; 26: 381-388.
84. Coste J, Montes B, Reynes J et al. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type I in plasma. J Med Virol 1996; 50: 293-302.
85. Damond F, Apetrei C, Descamps D et al. HIV-1 subtypes and plasma RNA quantification. AIDS 1999; 13: 286-287.
86. Parekh B, Phillips S, Granade T et al. Impact of HIV-1 subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses 1999; 15: 133-142.
87. O'Shea S, Chrystie I, Cranston R et al. Problems in the interpretation of HIV-1 viral load assays using commercial reagents. J Med Virol 2000; 61: 187-194.
88. de la Rosa R, Leal M, Pineda JA et al. Low levels of HIV-1 plasma viral load in patients infected with HIV-1 subtype B and advanced immunosuppression. J Infect 2001; 42: 4-7.
89. The Euroguidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. AIDS 2001; 15: 309-320.
90. Coll O, Fiore S, Floridia M et al. Pregnancy and HIV infection: A European consensus on management. AIDS 2002; 16 (Suppl 2): S1-S18.
91. Frenkel L, Wagner L, Demeter L et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995; 20: 1321-1326.
92. Kully C, Yerly S, Erb P et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy'Study. J Infect Dis 1999; 179: 705-708.
93. Palumbo P, Holland B, Dobbs T et al 2000. Antiretroviral resistance mutations among pregnant HIV-infected women and their newborns in the US: Vertical transmission and clades. J Infect Dis 2001; 184: 1120-1126.
94. Welles SL, Pitt J, Colgrove RC et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14: 263-271.
95. Eastman PS, Shapiro DE, Coombs RW et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177: 557-564.
96. Ekpini R, Nkengasong J, Sibailly TS et al. Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002; 16: 635-640.
97. Larbalestier N, Mullen J, O'Shea S et al. Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS 2003; 17: 2665-2667.
98. Read P, Costelloe S, Mullen J et al. New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines. HIV Med 2008; 9: 448-451.
99. Martin F, Navaratne L, Khan W et al. Pregnant women with HIV infection can expect healthy survival. J Acquir Immune Defic Sydnr 2006; 43: 186-192.
100. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomised Trial. Lancet 1999; 354: 795-802.
101. Eshleman SH, Mracna M, Guay L et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-1957.
102. Martinson N, Morris L, Gray G et al. HIV resistance and transmission following single dose nevirapine in a PMTCT cohort. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 38].
103. Eshleman SH, Hoover D, Chen S et al. Comparison of nevirapine resistance in women with subtype C compared with subtypes A and D following single-dose NVP. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 799].
104. Cunningham CK, Chaix ML, Rekacewicz C et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002; 186: 181-188.
105. Lyons F, Coughlan S, Byrne C, Hopkins S, Hall WW, Mulcahy F. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19: 63-67.
106. Chaix M, Rekacewicz C, Bazin B et al. Genotypic resistance analysis in French women participating in PACTG 316/ANRS 083. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 470].
107. Palumbo P, Holland B, Dobbs T et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: Vertical transmission and clades. J Infect Dis 2001; 184: 1120-1126.
108. Mofenson L, Lambert JS, Stiehm A et al. Association of ZDV genotypic resistance with perinatal transmission in women receiving ZDV in Pediatric AIDS Clinical Trials Group (PACTG) Protocol 185. 13th International AIDS Conference. Durban, South Africa, July 2000 [Abstract 1229].
109. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-2093.
110. Jungmann EM, Mercey D, de Ruiter A et al. Is first trimester exposure to antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities ? Sex Trans Infect 2001; 77: 441-443.
111. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. New Engl J Med 2000; 343: 1608-1614.
112. Brocklehurst P. Interventions for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Revs 2001, (Art. No. CD000102) doi 10.1002/14651858.CD000102.
113. Volmink J, Siegfried N, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Revs. 2007, (Art. No. CD003510) doi 10.1002/14651858.CD003510.
114. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New Engl J Med 1994; 331: 1173-1180.
115. Lallemant M, Jourdain G, Le Coeur S et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type I. New Engl J Med 2000; 343: 982-991.
116. Cooper ER, Nugent R, Diaz C et al. After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy, and subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996; 174: 1207-1211.
117. Mayaux MJ, Teglas J-P, Mandelbrot L et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus type-1 transmission in France. J Pediatr 1997; 131: 857-862.
118. The European Collaborative Study. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. Br J Obstet Gynaecol 1998; 105: 704-709.
119. Wade NA, Birkhead GS, Warren BL et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New Engl J Med 1998; 339: 1409-1414.
120. Wiktor SV, Ekpini E, Karon JM et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial. Lancet 1999; 353: 781-785.
121. Ditrame ANRS 049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet 1999; 354: 2050-2051.
122. The European Mode of Delivery Collaboration. Elective caesarian-section vs. vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial. Lancet 1999; 353: 1035-1039.
123. Warszawaski J, Tubiana R, Le Chenadec J et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22: 289-299.
124. Jackson J, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. The Lancet 2003; 362: 859-868.
125. Moodley D, Moodley J, Coovadia H et al. A multicenter randomized controlled trial of nevirapine vs. a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-735.
126. Ripamonti D, Cattaneo D, Airoldi M et al. Atazanavir-based HAART in pregnancy. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 742].
127. Peytavin G, Tubiana R, Ferreira C et al. Genital tract diffusion of different HIV PI in HIV-1-infected pregnant women. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 744].
128. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Towards universal access: recommendations for a public health approach -2006 version. Geneva, World Health Organization, 2006.
129. Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-228.
130. McIntyre JA, Martinson N, Gray GE et al. Addition of short course combivir to single-dose viramune (sdNVP) for the prevention of mother-to-child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 2005 [Abstract TuFo0204].
131. Chaix ML, Ekouevi DK, Rouet F et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193: 482-487.
132. Dabis F, Bequent L, Ekouevi DK et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19: 309-318.
133. Shapiro D, Tuomala R, Pollack H et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2004 [Abstract 99].
134. European Collaborative Study. Mother to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458-465.
135. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet 1999; 354: 1112-1115.
136. Martin JL, Brown DE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogues on human DNA poymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743-2749.
137. U.S. Food and Drug Administration. Important drug warning -Zerit and Videx. [Retyped letter from Bristol-Myers Squibb Company, dated 5 January 2001]. http://www.fda.gov/medwatch/safety/2001/ zerit&videx_letter.htm 2001.
138. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127: 948.
139. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127: 948.
140. Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. AIDS 2003; 32: 298-302.
141. Gonzalez-Tome MI, Ramos J, Solis I et al. Gestational Diabetes and ART in pregnant HIV-1-infected women. 12th Conference on Retroviruses and Opportunistic Infections, February 2005, Boston, MA [Abstract 68].
142. Timmermans S, Tempelman C, Godfried MH et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005; 19: 795-799.
143. Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol 2002; 10: 187-191.
144. Tang JH, Sheffield JS, Grimes J et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107: 1115-1119.
145. Hitti J, Andersen J, McComsey G et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstetr Gynecol 2007; 196: 331.
146. Hanlon M, O'Dea S, Clarke S, Mulcahy F. Maternal hepatotoxicity with boosted saquinavir as part of combination ART in pregnancy. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 753].
147. Mears A, Lilaonitkul M, Phillips D et al. Kaletra ™ in pregnancy: a retrospective study of 100 women. 13th British HIV Association Conference, Edinburgh, UK, 23-25 April 2007 [Abstract P17].
148. Natha M, Hay P, Taylor G et al. Atazanavir use in pregnancy: A report of 33 cases. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 750].
149. Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected pregnant women: A review of the FDA's adverse event reporting system. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 944].
150. Lyons F, Butler K, Coulter Smith S, Mulcahy F. National guidelines for the management of HIV-1 in pregnancy. Ir Med J 2006; 99: 152-154.
151. Lyons F, Hopkins S, Kelleher B et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255-260.
152. Hitti J, Frenkel L, Huang S et al 2004. Toxicity with continuous nevirapine in pregnancy: Results from PACTG1022. J Acquir Immune Defic Syndr 2004; 36: 772-776.
153. Money D, Khoo D, MacDonald G et al. A comparison of toxicity in nevirapine vs. protease inhibitor containing HAART regimens in pregnant women. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 784].
154. Bershoff-Matcha SJ, Mundy LM, Henry JV. 2004 Adverse events to nevirapine therapy during pregnancy. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 939].
155. Natarajan U, Pym A, McDonald C et al. The safety of nevirapine in pregnancy. HIV Med 2007; 8: 64-69.
156. Phanuphak N, Teeratakulpisarn S, Apornpong T, Phanuphak P. Comparison of hepatic and cutaneous toxicities in pregnant women with baseline CD4 <250cells/mm 3 vs. those with CD4 >250cells/mm 3 receiving nevirapine (NVP)-containing highly active antiretroviral therapy (HAART) for the prevention of mother-to-child transmission (PMTCT) in Thailand. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract 322].
157. Phanuphak N, Apornpong T, Intarasuk S, Teeratakulpisarn S, Phanuphak P. Toxicities from nevirapine in HIV-infected males and females, including pregnant females with various CD4 cell counts. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 22].
158. Phanupak N, Apornpong T, Limpongsanurak S et al. Toxicities from nevirapine-based ART regimens in pregnant women with CD4 counts between 250 and 350cells/mm 3. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 752].
159. Thomas T, Amornkul P, Mwidau J et al. Preliminary findings: Incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trial using HAART to prevent mother-to-child HIV transmission. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005 [Abstract 809].
160. Lorenzi P, Spicher VM, Laubereau B et al. Antiretroviral therapies in pregnancy: Maternal, foetal and neonatal effects. AIDS 1998; 12: F241-F247.
161. The European Collaborative Study, the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-2920.
162. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-2339.
163. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-1026.
164. Fiore S, Newell M-L, Trabattoni D et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70: 143-150.
165. Martin F, Taylor GP. Increased rates of pre-term delivery are associated with the initiation of HAART during pregnancy: A single centre cohort study. J Infect Dis 2007; 196: 558-561.
166. Boer K, Nellen JF, Patel D et al. The AmRo Study: Pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. Br J Obstet Gynaecol 2007; 114: 148-155.
167. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S. Births: Final data for 2004. Natl Vital Stat Rep 2006; 55: 1-101.
168. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG, for the Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007; 119: e900-e906.
169. Morris AB, Cu-Uvin S, Harwell JI et al. Multicentre review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Sydnr 2000; 25: 306-311.
170. Shapiro DE, Tuomala R, Samelson R et al. Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-1- infected women in 1998-1999 [PACTG 367]. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000 [Abstract 664].
171. Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. New Engl J Med 2002; 346: 1863-1870.
172. Beckerman K, Covington D, Garcia P et al. Association between antiretroviral therapy during pregnancy and prematurity/low birth weight. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 97].
173. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 1195-1201.
174. Suy A, Martinez E, Coll O et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66.
175. Wimalasundera RC, Smith JH, Thom S et al. Is pre-eclampsia in HIV positive women treated with antiretroviral therapy a manifestation of immune reconstitution. Lancet 2002; 360: 1152-1154.
176. Stratton P, Tuomala RE, Abboud R et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: A report of the women and infants transmission study. J Acquir Immune Defic Sydnr Hum Retrovirol 1999; 20: 179-186.
177. Mattar R, Amed AM, Lindsey PC, Sass N, Daher S. Preeclampsia and HIV infection. Eur J Obstet Gynecol Reproduct Biol 2004; 117: 240-241.
178. Gray G, McIntyre J, Jivkov B et al. Preliminary efficacy, safety, tolerability, and pharmacokinetics of short course regimens of nucleoside analogs for the prevention of mother-to-child transmission of HIV. 13th International AIDS Conference. Durban, South Africa, July 2000 [Abstract TuOr B355].
179. Moodley J, Moodley D, Pillay K et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-1333.
180. O'Sullivan MJ, Boyer PJ, Scott GB et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993; 168: 1510-1516.
181. Odinecs A, Nosbich C, Keller RD, Baughman WL, Unadkat J. In vivo maternal-fetal pharmacokinetics of stavudine (2′, 3′-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40: 196-202.
182. Rodman JH, Flynn PM, Robbins B et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type-1-infected women and newborn infants. J Infect Dis 1999; 180: 1844-1850.
183. Best BM, Mirochnick M, Capparelli E et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20: 553-560.
184. Burchett S, Best B, Mirochnick M et al. Tenofovir pharmacokinetics during pregnancy, at delivery and post partum. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 738b].
185. Mackie NE, Fidler S, Tamm N et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: Relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5: 180-184.
186. Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20: 803-805.
187. Taylor GP, Lyall E, Back D, Ward C, Tudor-Williams G. Pharmacological implications of prolonged in utero exposure to nevirapine. Lancet 2000; 355: 2134-2135.
188. Aweeka F, Stek A, Best B et al. Lopinavir protein-binding during pregnancy. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 787].
189. Khoung-Josses M-A, Boussairi A, Herida M, Abbas S, Mechali D. Nelfinavir plasma concentrations in 40 pregnant women. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 707].
190. Vithayasai V, Moyle GJ, Supajatura V, Wattanatchariya N, Kanshana S, Sirichthaporn P et al. Safety and efficacy of saquinavir soft-gelatin capsules plus zidovudine plus optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Sydnr 2002; 30: 410-412.
191. Khan W, Hawkins DA, Moyle GJ et al 2004. Pharmacokinetics, safety, tolerability and efficacy of saquinavir hard-gel capsules/ritonavir (SQV/ r) plus 2 nucleosides in HIV-infected pregnant women. 15th International AIDS Conference. Bangkok, Thailand, July 2003 [Abstract ThPeB7064].
192. Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430-436.
193. Burger DM, Eggink A, van der Ende ME et al. The pharmacokinetics of Saquinavir new tablet formulation + ritonavir (1000/100mg BID) in HIV-1 infected pregnant women. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 741].
194. Lyons F, Lechelt M, Magaya V, Issa R, de Ruiter A. Adequate trough lopinavir levels with standard dosing in pregnancy. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 709].
195. Dumond J, Yeh R, Patterson K et al. First dose and steady-state genital tract pharmacokinetics of 10 antiretroviral drugs in HIV-infected women: Implications for pre- and post- exposure prophylaxis. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 129].
196. National Collaborating Centre for Women's and Children's Health, National Institute of Clinical Excellence. Antenatal care: Routine care for the healthy pregnant woman. London, RCOG Press, 2003.
197. Lee A. Common problems in pregnancy. In: Lee A, Inch S, Finnigan D, eds. Therapeutics in Pregnancy and Lactation. Oxford, Radcliffe Medical Press, 2000: 23-36.
198. Anti-emetics use in pregnancy: Overview by the National Teratology Information Service in Leeds (January 2004). NK 2005.
199. van Benthem BH, de Vincenzi I, Delmas MC, Larsen C, van den Hoek A, Prins M. Pregnancies before and after HIV diagnosis in a European cohort of HIV-infected women. European Study on the Natural History of HIV Infection in Women. AIDS 2000; 14: 2171-2178.
200. Massad LS, Springer G, Jacobson L et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 2004; 18: 281-286.
201. Maiques V, Garcia-Tejedor A, Perales A, Cordoba J, Esteban RJ. HIV detection in amniotic fluid samples: Amniocentesis can be performed in HIV pregnant women? Eur J Obstetr Gynecol Reproduct Biol 2003; 108: 137-141.
202. Somigliana E, Bucceri AM, Tibaldi C et al. Early invasive diagnostic techniques in pregnant women who are infected with the HIV: A multicenter case series. Am J Obstetr Gynecol 2005; 193: 437-442.
203. Coll O, Suy A, Hernandez S et al. Prenatal diagnosis in human immunodeficiency virus-infected women: A new screening program for chromosomal anomalies. Am J Obstet Gynecol 2006; 194: 192-198.
204. Williams D. Renal disease in pregnancy. Curr Opin Obstetr Gynecol 2004; 14: 166-174.
205. Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1: Maternal immune sTatus and obstetric factors: the European collaborative study. AIDS 1996; 10: 1675-1681.
206. Mandelbrot L, Mayaux MJ, Bongain A et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: The French Perinatal Cohort. Am J Obstet Gynaecol 1996; 175: 661-667.
207. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies. AIDS 2001; 15: 357-368.
208. Grubert TA, Reindell D, Kastner R, Lutz-Friedrich R, Belohradsky BH, Dathe O. Complications after caesarean section in HIV-1-infected women not taking antiretroviral therapy. Lancet 1999; 354: 1612-1613.
209. Maiques-Montesinos V, Cervera-Sanchez J, Bellver-Pradas J et al. Post caesarean morbidity in HIV-positive women. Acta Obstet Gynecol Scand 1999; 78: 789-792.
210. Semprini E, Castagna C, Ravizza M et al. The incidence of complications after Caesarean section in 156 HIV-1-positive women. AIDS 1995; 9: 913-917.
211. Beckerman K, Morris AB, Stek A. Mode of delivery and the risk of vertical transmission of HIV-1. N Engl J Med 1999; 341: 205-206.
212. Garcia-Bujalance S, Ruiz G, De Guevara CL et al. Quantitation of human immunodeficiency virus type 1 RNA loads in cervicovaginal secretions in pregnant women and relationship between viral loads in the genital tract and blood. Eur J Clin Microbiol Infect Dis 2004; 23: 111-115.
213. Clinical Effectiveness Support Unit, RCOG. Induction of labour. Evidence based guideline number 9. London, RCOG Press, 2001.
214. National Collaborating Centre for Women's and Children's Health, National Institute of Clinical Excellence. Caesarean section. Clinical Guideline CG13. London, RCOG Press, 2004.
215. The International Perinatal HIV Group. Mode of delivery and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies. New Engl J Med 1999; 340: 977-987.
216. Burns DN, Landesman S, Wright DJ et al. Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175: 1206-1210.
217. Morrison JJ, Rennie JM, Milton P. Neonatal respiratory morbidity and mode of delivery at term: Influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102: 101-106.
218. Towers CV, Deveikis A, Asrat T, Major C, Nageotte MP. A 'bloodless cesarean section'and perinatal transmission of the human immunodeficiency virus. Am J Obstet Gynecol 1998; 179 (3, pt 1): 708-714.
219. Duarte G, Read JS, Gonin R et al. Mode of delivery and postpartum morbidity in Latin American and Caribbean countries among women who are infected with human immunodeficiency virus-1: The NICHD international Site Development Initiative (NISDI) Perinatal Study. Am J Obstet Gynecol 2006; 195: 215-229.
220. Fiore S, Newell ML, Thorne C. European HIV in Obstetrics Group. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18: 933-938.
221. Parisaei M, Anderson J, Erskine KJ, Gann S. Experience of delivering women with HIV in an inner city London hospital 1994-2004. Int J STD AIDS 2007; 18: 527-530.
222. Duarte G, Read J, Gonin R et al. Mode of delivery and postpartum morbidity among HIV-1-infected women in Latin America and the Caribbean: The NICHD International Site Development Initiative Perinatal Study. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 69].
223. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83: 1253-1265.
224. Gilbert PB, McKeague IW, Eisen G et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22: 573.
225. Kanki PJ, Travers KU, MBoup S et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343: 943-946.
226. Poulsen AG, Kvinesdal BB, Aaby P et al. Lack of evidence of vertical transmission of human immunodeficiency virus type 2 in a sample of the general population in Bissau. J Acquir Immune Defic Sydnr 1992; 5: 25-30.
227. O'Donovan D, Ariyoshi K, Milligan P et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000; 14: 441-448.
228. Cavaco-Silva P, Taveira NC, Rosado L et al. Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. J Virol 1998; 72: 3418-3422.
229. Marlink R, Kanki P, Thior I et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265: 1587-1590.
230. Jaffer S, Grant AD, Whitworth J, Smith PG, Whittle H. The natural history of HIV-1 and HIV-2 infections in adults in Africa: A literature review. Bull WHO 2004; 82: 462-469.
231. Shanmugam V, Switzer WM, Nkengasong JN et al. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. J Acquir Immune Defic Sydnr 2000; 24: 257-263.
232. Matheron S, Pueyo S, Damond F et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS Cohort. AIDS 2003; 17: 2593-2601.
233. Ariyoshi K, Jaffer S, Alabi AS et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. AIDS 2000; 14: 339-344.
234. Parkin NT, Shapiro J. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antiviral Ther 2004; 9: 3-12.
235. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999; 13: 1477-1483.
236. Reid P, MacInnes H, Cong M, Heneine W, Gerardo Garcia-Lerma J. Natural resistance of human immunodeficiency virus type 2 to zidovudine. Virology 2005; 336: 251-264.
237. Parreira R, Monteiro F, Padua E et al. Natural polymorphisms of HIV type 2 pol sequences from drug-naïve individuals. AIDS Res Hum Retroviruses 2006; 22: 1178-1182.
238. Descamps D, Desbois D, Damond F et al. In vitro phenotypic suceptibility of HIV-2 clinical isolates to protease inhibitors: Amprenavir, atazanavir, lopinavir and tipranavir. Antiviral Ther 2006; 11 (Suppl 1): S103.
239. Adje-Toure CA, Cheingsong R, Garcia-Lerma G et al. Antiretroviral therapy in HIV-2-infected patients: Changes in plasma viral load, CD4 cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS 2003; 17 (Suppl 3): S49-S54.
240. Rodes B, Holguin A, Soriano V et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38: 1370-1374.
241. Jallow S, Kaye S, Alabi AS et al. Virological and immunological response to combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in the Gambia. AIDS 2006; 20: 1455-1458.
242. Descamps D, Damond F, Matheron S et al. High frequency of selection of K65R and Q151M mutations in HIV-2-infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74: 197-201.
243. Damond F, Collin G, Matheron S et al. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antiviral Ther 2005; 10: 861-865.
244. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathogen 2006; 2: E10.
245. Gibb DM, Goodall RL, Dunn DT et al. Mother-to-child transmission of hepatitis C virus: Evidence for preventable peripartum transmission. Lancet 2000; 356: 904-907.
246. Resti M, Azzari C, Galli L et al. Maternal drug use is a pre-eminent risk factor for mother-to-child hepatitis C virus transmission: Results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002; 185: 567-572.
247. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15250 pregnant women. Hepatology 2000; 31: 751-755.
248. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: Risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27: 108-117.
249. Spencer JD, Latt N, Beeby PJ et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: Rate of infection and assessment of risk factors for transmission. J Viral Hepat 1997; 4: 395-409.
250. Zanetti AR, Tanzi E, Paccagnini S et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345: 289-291.
251. Ruiz-Extremera A, Salmeron J, Torres C et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000; 19: 511-516.
252. Tovo PA, Palomba E, Ferraris G et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Inf Dis 1997; 25: 1121-1124.
253. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): A meta-analysis. Int J Epidemiol 2003; 32: 727-734.
254. Kreitchmann R, Fuchs SC, Suffert T, Preussler G. Perinatal HIV-1 transmission among low income women participants in the HIV/AIDS Control Program in Southern Brazil: A cohort study. BJOG 2004; 111: 579-584.
255. Magnani G, Degli Antoni AM, Cocca G et al. Risk of materno-fetal transmission of HIV infection with antiretroviral therapy and Caesarian section: Experience of the Parma Group. Acta Biomed Ateneo Parmense 2000; 71 (Suppl 1): 563-566.
256. Zuckerman J, Harrison TJ, Zuckerman AJ. Prevention. In: Thomas HC, Zuckerman AJ. eds. Viral Hepatitis. London, Churchill Livingstone, 2004.
257. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European paediatric hepatitis C virus infection. J Infect Dis 2000; 181: 419-424.
258. Beasley RP, Hwang LY, Szmuness W et al. HBIG prophylaxis for perinatal HBV infections -final report of the Taiwan trial. Dev Biol Stand 1983; 54: 363-375.
259. Li XM, Yang YB, Hou HY et al. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol 2003; 9: 1501-1503.
260. Menendez C, Sanchez-Tapias J, Kahigwa E et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999; 58: 215-220.
261. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann NY Acad Sci 2000; 918: 287-297.
262. Jullien V, Urien S, Hirt D et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006; 50: 3548-3555.
263. Rongkavilit C, Van Heewsijk R, Limpongsanurak S et al. Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J Acquir Immune Defic Sydnr 2002; 29: 455-463.
264. Bryson YJ, Stek A, Mirochnick M et al. A Phase I study of safety, pharmacokinetics and antiviral activity of combination nelfinavir (NFV), ZDV and 3TC in HIV-infected pregnant women and their infants. PACTG 353. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000 [Abstract 715].
265. Faye A, Bertone C, Teglas JP et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 2002; 21: 518-525.
266. Shetty AK, Coovadia HM, Mirochnick M et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Sydnr 2003; 34: 482-490.
267. Vankandondera J, Luchters S, Hassink E, Pakker N, Mmiro F, Okong P. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA Study). 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France, July 2003 [Abstract LB07].
268. Boucher FD, Modlin JF, Weller S et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137-144.
269. Capparelli EV, Mirochnick M, Dankner WM et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142: 47-52.
270. Taha TE, Kumwenda N, Gibbons A et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission on HIV-1: NVAZ Randomised Clinical Trial. Lancet 2003; 362: 1171-1177.
271. Mirochnick M, Dorenbaum A, Blanchard S et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Sydnr 2003; 33: 153-156.
272. Schmitz T, Weizsaecker K, Feiterna-Sperling C, Eilers E, Obladen M. Exposure to HIV and antiretroviral medication as a potential cause of necrotizing enterocolitis in term neonates. AIDS 2006; 20: 1082-1083.
273. UK Department of Health. HIV Post-Exposure Prophylaxis: Guidance from the UK Chief Medical Officer's Expert Advisory Group on AIDS. London, UK Department of Health, 2004. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_4083638
274. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Sydnr 2002; 30: 200-215.
275. Hanson IC, Antonelli TA, Sperling RS et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Sydnr Hum Retrovir 1999; 15: 463-467.
276. The European CS. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003; 111: E52-e60.
277. Culnane M, Fowler M, Lee SS et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281: 151-157.
278. Barret B, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-1785.
279. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-387.
280. Dominguez K, Bertolli J, Fowler M et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children <5 years of age, Pediatric Spectrum of HIV Disease Project (PSD), USA. Ann NY Acad Sci 2000; 198: 236-246.
281. Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants: Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann NY Acad Sci 2000; 918: 222-235.
282. Bulterys M, Nesheim S, Abrams EJ et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci 2000; 918: 212-221.
283. Poirier MC, Divi RL, Al-Harthi L et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Sydnr 2003; 33: 175-183.
284. Hankins CD, Tookey PA, Lyall E, Peckham CS. Follow-up of children exposed to antiretroviral therapy in pregnancy (CHART): A role for HIV physicians. HIV Med 2004; 5 (Suppl 2): 35-36.
285. Hankin CD, Newell ML, Tookey PA. Long-term follow-up of uninfected children born to HIV-infected women and exposed to antiretroviral therapy: Survey of parents' and health professionals' views. AIDS Care 2007; 19: 482-486.
286. Hankin C, Lyall H, Peckham C, Tookey P. Monitoring death and cancer in children born to HIV-infected women in England and Wales: Use of HIV surveillance and national routine data. AIDS 2007; 21: 867-869.
287. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998; 24: 247-250.
288. Giaquinto C, De Romeo A, Giacomet V et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15: 1074-1075.
289. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S, Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17: 2053-2061.
290. Landreau-Mascaro A, Barret B, Mayaux MJ, Tardieu M, Blanche S. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. The Lancet 2002; 359: 583-584.
291. Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S. A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA 1996; 275: 1342-1348.
292. Lambert JS, Harris DR, Stiehm ER et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Sydnr 2003; 34: 512-519.
293. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero vs. intrapartum transmission of HIV-1. New Engl J Med 1992; 327: 1246-1247.
294. Simonds RJ, Brown T, Thea DM et al. Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. Perinatal AIDS Collaborative Transmission Study. AIDS 1998; 12: 1545-1549.
295. Reisler RB, Thea DM, Pliner V et al. Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: A comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction. J Acquir Immune Defic Sydnr 2001; 26: 93-102.
296. Burgard M, Blanche S, Mayaux MJ et al. Impact of neonatal prophylaxis on early diagnosis in newborns. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract 868].
297. Nastouli E, Atkins M, Seery P, Hamadache D, Lyall H. False-positive HIV antibody results with ultrasensitive serological assays in uninfected infants born to mothers with HIV. AIDS 2007; 21: 1222-1223.
298. Children's HIV National Network (CHINN). Children's HIV National Network (CHINN) Review 2005. London, Department of Health, 2006. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyandGuidance/DH_4139814
299. Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1-infected children in the United Kingdom and Ireland. BMJ 2003; 327: 1019.
300. Gaillard P, Fowler MG, Dabis F et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: From animal studies to randomised clinical trials. J Acquir Immune Defic Sydnr 2004; 35: 178-187.
301. Nduati R, John G, Mbori-Ngacha D et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomised clinical trial. JAMA 2000; 283: 1167-1174.
302. Leroy V, Karon JM, Alioum A et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2004; 16: 631-641.
303. The PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): A randomised, double-blind, placebo-controlled trial. Lancet 2002; 359: 1178-1186.
304. Alioum A, Cortina-Borja M, Dabis F et al. Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: Comparing statistical methods. Am J Epidemiol 2003; 158: 596-605.
305. The Breast Feeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: An individual patient data meta-analysis. J Infect Dis 2004; 189: 2154-2166.
306. Willumsen JF, Newell ML, Filteau S et al. Variation in breastmilk HIV-1 viral load in left and right breasts during the first 3 months of lactation. AIDS 2001; 15: 1896-1897.
307. Willumsen JF, Filteau S, Coutsoudis A et al. Breastmilk RNA viral load in HIV-infected South African women: Effects of subclinical mastitis and infant feeding. AIDS 2002; 17: 407-414.
308. Dabis F, Msellati P, Meda N et al. 6 month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. DITRAME Study Group. Diminution de la Transmission Mère-Enfant. Lancet 1999; 353: 756-792.
309. Brooks Jackson J, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-868.
310. Parkin NT, Schapiro J. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antiviral Therapy (2004); 9: 3-12.
311. Moodley D, Pillay K, Naidoo K et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001; 41: 732-741.
312. Wang Y, Livingston E, Patil S et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: An AIDS clinical trial group study. J Infect Dis 1999; 180: 1536-1541.
313. Rongkavilit C, Thaithumyanon P, Chuenyam T et al. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother 2001; 45: 3585-3590.
314. Johnson GM, Rodman JH, McDowell J, Wiznia A. Preliminary analysis of abacavir succinate pharmacokinetics in neonates differs from adults and young children. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000 [Abstract 720].
315. Simonds RJ, Lindegren ML, Thomas P et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaulation Working Group. N Engl J Med 1995; 332: 786-790.